PE
PTGX icon

Point72 Europe’s Protagonist Therapeutics PTGX Stock Holding History

Point72 Europe’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-45,317
Closed -$2.04M – 157
2024
Q3 		$2.04M Buy
+45,317
New +$1.83M 0.13% 101

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Europe's PTGX Position: Q4 2024 in Review

Point72 Europe sold out of Protagonist Therapeutics (PTGX) in Q4 2024, closing a stake of 45,317 shares — an estimated $2.04M sold.

Point72 Europe first reported a position in PTGX in Q3 2024 and held it in 1 quarter. The position peaked at $2.04M in Q3 2024. 241 funds tracked by Wall St. Rank hold PTGX as of Q4 2024.

  • Point72 Europe reported no remaining Protagonist Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Point72 Europe sold 45,317 Protagonist Therapeutics shares in Q4 2024, an estimated $2.04M.
  • Point72 Europe first reported a position in Protagonist Therapeutics in Q3 2024 and held it in 1 quarter.
  • Point72 Europe's Protagonist Therapeutics position peaked at $2.04M in Q3 2024.
  • 241 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2024.

Based on Point72 Europe's 13F filing for Q4 2024, filed 14 Feb 2025.